Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT05267054 Recruiting - Clinical trials for Refractory Diffuse Large B-cell Lymphoma

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab

Start date: April 25, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The primary purpose of this study is to assess the safety and tolerability of ociperlimab (BGB-A1217) in combination with tislelizumab (BGB-A317) or rituximab in participants with relapsed or refractory (R/R) diffuse large B cell lymphoma (DLBCL)

NCT ID: NCT05265975 Recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL

SWATCH
Start date: April 7, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A Single-arm, Phase Ⅰ/Ⅱ Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of ATG-010 in Combination with Lenalidomide and Rituximab (R2) in Adult Patients with Relapsed/Refractory DLBCL and iNHL Who are Ineligible for High-dose Chemotherapy (HDC) or Autologous Stem Cell Transplant (A SCT).

NCT ID: NCT05263583 Recruiting - Lymphoma, B-Cell Clinical Trials

Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

Start date: December 9, 2022
Phase: Phase 2
Study type: Interventional

This is a multi-center Phase 2 study to determine the safety and efficacy of sepantronium bromide (SepB) in adult patients with relapsed or refractory high-grade B-cell lymphoma

NCT ID: NCT05260957 Recruiting - Clinical trials for Refractory Non-Hodgkin Lymphoma

CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

Start date: December 14, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to test if a combination treatment of chimeric antigen receptor (CAR) T-cell therapy, Mosunetuzumab, and Polatuzumab Vedotin will result in tumor reduction.

NCT ID: NCT05260619 Recruiting - Clinical trials for Central Nervous System Lymphoma

Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma

PCNSL-LEM
Start date: April 1, 2022
Phase: Phase 2
Study type: Interventional

The study will include 28 patients with primary CNS DLBCL who are ineligible with autologous hematopoietic stem cell transplantation or whole brain radiation therapy as consolidation therapy. Induction treatment will include Rituximab and high dose methotrexate protocol (containing at least methotrexate and one more chemotherapy agent). Patients with MRI documented response CR or PR after induction chemotherapy will enter the study protocol of lenalidomide maintenance (at a dose of 15 mg per day, on days 1 to 21 of each 28-day cycle) for a maximum of 12 cycles, withdrew consent, the disease progressed, or unacceptable toxic effects occurred.

NCT ID: NCT05257785 Recruiting - Lymphoma Clinical Trials

Lymfit to Improve the Fitness and Quality of Life in Lymphoma Survivors

Lymfit_RCT
Start date: January 15, 2022
Phase: N/A
Study type: Interventional

This randomized control trial seeks to determine whether a tailored and supervised exercise program adopting mobile-health technology will be able to improve fitness and quality of life among lymphoma survivors.

NCT ID: NCT05257018 Recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse

Start date: February 26, 2022
Phase: Phase 2
Study type: Interventional

This is a double-center, single-arm, phase 2 study to evaluate the efficacy and safety of R-CDOP regimen combined with intrathecal methotrexate in chemo-naive diffuse large B-cell lymphoma patients with high-risk of CNS relapse.

NCT ID: NCT05256641 Recruiting - Clinical trials for Diffuse Large B-Cell Lymphoma

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

Start date: January 23, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back. Acalabrutinib is a small molecular inhibitor that may interfere with the ability of cancer cells to grow and spread.

NCT ID: NCT05255601 Recruiting - Clinical trials for Lymphoma, Non-Hodgkin

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

RELATIVITY-069
Start date: September 13, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.

NCT ID: NCT05255354 Recruiting - Clinical trials for Mantle Cell Lymphoma

Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

Start date: June 1, 2022
Phase:
Study type: Observational

In this study, invesigators propose to analyze 150 DLBCL patients, 50 MCL patients, and 100 FL patients to determine the clinical utility of ctDNA- as well as circulating tumor cell (CTC)-based MRD assessment in CAR therapy patients. The project detailed in this protocol will utilize the clonoSEQ platform as specific quantification of residual DLBCL/FL/MCL and correlate its results with radiologic assessment of disease and clinical outcomes. Invesitgators predict there will be a strong correlation between ctDNA and PET/CT and dynamic changes in ctDNA will precede radiologic evidence of disease recurrence in patients following CAR therapy.